PARP1-selective inhibitor DSB1559 demonstrates superior efficacy and antitumor immunity in triple-negative breast cancer
Open Access
- 7 October 2026
- journal article
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 14 (10) , e014578
Abstract
Background: Poly (ADP-ribose) polymerase inhibitors (PARPis) have improved outcomes of BRCA-associated breast cancer; however, treatment-related toxicity remains a major clinical challenge. Currently approved PARPis broadly inhibit multiple members of the PARP protein family. However, preclinical studies suggest that inhibition of PARP1 alone is sufficient to drive antitumor efficacy. In contrast, inhibition of PARP2 has been implicated in hematological toxicities seen in patients receiving PARPi therapy. Therefore, selectively inhibiting PARP1 may reduce toxicity for patients. Here, we characterize and test the PARP1-selective inhibitor DSB1559 in preclinical models of Brca1-associated triple-negative breast cancer (TNBC). Methods: Pharmacokinetic/pharmacodynamic assays were performed to examine DSB1559 potency, selectivity, and in vivo behavior. Immunocompetent FVB/n mice bearing Brca1-deficient TNBC (CMV-Cre;Brca1 fl/fl ;Trp53 fl/fl ) tumors were treated with olaparib or DSB1559 and followed for survival. Flow cytometry and bulk RNA-sequencing were performed to measure the effects on the tumor microenvironment (TME). Results: DSB1559 had superior selectivity for PARP1 and increased overall survival compared with olaparib. Analysis of the TME revealed a significant increase in cytotoxic T-cells, activated dendritic cells, and genes associated with antitumor immunity in mice treated with DSB1559. Conclusions: Taken together, DSB1559 is a highly selective PARP1 inhibitor that demonstrates superior efficacy and antitumor immune response compared with olaparib. A structurally related, clinical lead compound (DSB2455) is now being tested in a phase Ia/Ib clinical trial ( NCT06458712 ).Keywords
Funding Information
- NIH DF/HCC SPORE in Breast Cancer (P50 CA168504)
- Canadian Institute of Health Postdoctoral Fellowship (194068)
- NIH NCI (P50 CA168504)
- NIH NCI (R01 CA307291)
- NIH NCI (R37 CA 269499)
- Susan G. Komen Foundation (CCR18547597)
- Duke Street Bio Ltd (N/A)
- The Terri Brodeur Breast Cancer Foundation (N/A)
- The Harvard Ludwig Center (N/A)
- Concern Foundation (N/A)
This publication has 55 references indexed in Scilit:
- Targeting PARP1: A Promising Approach for Next-Generation Poly (ADP-ribose) Polymerase InhibitorsCurrent Breast Cancer Reports, 2025
- PARP inhibitors in gliomas: Mechanisms of action, current trends and future perspectivesCancer Treatment Reviews, 2024
- Combination of Resveratrol and PARP inhibitor Olaparib efficiently deregulates homologous recombination repair pathway in breast cancer cells through inhibition of TIP60-mediated chromatin relaxationMedical Oncology, 2024
- Pharmacokinetics and Pharmacodynamics of PARP Inhibitors in OncologyClinical Pharmacokinetics, 2022
- Combination of talazoparib and olaparib enhanced the curcumin-mediated apoptosis in oral cancer cells by PARP-1 trappingJournal of Cancer Research and Clinical Oncology, 2022
- Unbound Brain-to-Plasma Partition Coefficient, Kp,uu,brain—a Game Changing Parameter for CNS Drug Discovery and DevelopmentPharmaceutical Research, 2022
- High Amount of Transcription Factor IRF8 Engages AP1-IRF Composite Elements in Enhancers to Direct Type 1 Conventional Dendritic Cell IdentityImmunity, 2020
- Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast CancerJAMA Oncology, 2019
- PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian CancerCell Reports, 2018
- A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancerEuropean Journal of Cancer, 2013